Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00651157 · ClinicalTrials.gov registry record · Phase 2
Viral Therapy in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00651157: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00651157 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00651157, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This phase II trial is studying the side effects and how well viral therapy works in treating patients with metastatic melanoma. Viral therapy may be able to kill tumor cells without damaging normal cells.
Interventions
- BIOLOGICAL wild-type reovirus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-04 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00651157
The ClinicalTrials.gov registry entry for NCT00651157 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which wild-type reovirus is the first listed.
NCT00651157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00651157 about?
NCT00651157 is a clinical study titled "Viral Therapy in Treating Patients With Metastatic Melanoma". This phase II trial is studying the side effects and how well viral therapy works in treating patients with metastatic melanoma. Viral therapy may be able to kill tumor cells without damaging normal cells.
What is the current status of trial NCT00651157?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2008-04. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00651157?
The interventions under investigation include: wild-type reovirus (BIOLOGICAL).
Who is sponsoring clinical trial NCT00651157?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.